Aprea Therapeutics Inc (APRE) - Net Assets
Based on the latest financial reports, Aprea Therapeutics Inc (APRE) has net assets worth $11.64 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.32 Million) and total liabilities ($2.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Aprea Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.64 Million |
| % of Total Assets | 81.28% |
| Annual Growth Rate | N/A |
| 5-Year Change | -75.05% |
| 10-Year Change | N/A |
| Growth Volatility | 18.43 |
Aprea Therapeutics Inc - Net Assets Trend (2007–2024)
This chart illustrates how Aprea Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Aprea Therapeutics Inc for the complete picture of this company's asset base.
Annual Net Assets for Aprea Therapeutics Inc (2007–2024)
The table below shows the annual net assets of Aprea Therapeutics Inc from 2007 to 2024. For live valuation and market cap data, see Aprea Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $19.31 Million | +5.71% |
| 2023-12-31 | $18.26 Million | -28.78% |
| 2022-12-31 | $25.64 Million | -48.20% |
| 2021-12-31 | $49.51 Million | -36.03% |
| 2020-12-31 | $77.40 Million | -37.71% |
| 2019-12-31 | $124.24 Million | +341.55% |
| 2018-12-31 | $-51.44 Million | -43.82% |
| 2017-12-31 | $-35.77 Million | -1592.10% |
| 2007-12-31 | $-2.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aprea Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29387232700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.48K | 0.03% |
| Other Comprehensive Income | $-10.63 Million | -55.04% |
| Other Components | $350.97 Million | 1817.80% |
| Total Equity | $19.31 Million | 100.00% |
Aprea Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aprea Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seacera Group Bhd
KLSE:7073
|
$9.37 Million |
|
Toyo Ventures Holdings Bhd
KLSE:7173
|
$9.37 Million |
|
Knusford Bhd
KLSE:5035
|
$9.38 Million |
|
THUNDER GOLD CORP.
F:Z25
|
$9.38 Million |
|
Micronet Ltd
TA:MCRNT
|
$9.37 Million |
|
Vantage Corp
NYSE MKT:VNTG
|
$9.36 Million |
|
Rigsave S.P.A.
XETRA:H68
|
$9.36 Million |
|
GlobalData PLC
LSE:DATA
|
$9.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aprea Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,264,569 to 19,307,455, a change of 1,042,886 (5.7%).
- Net loss of 12,958,711 reduced equity.
- New share issuances of 16,140,356 increased equity.
- Other comprehensive income decreased equity by 16,106.
- Other factors decreased equity by 2,122,653.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.96 Million | -67.12% |
| Share Issuances | $16.14 Million | +83.6% |
| Other Comprehensive Income | $-16.11K | -0.08% |
| Other Changes | $-2.12 Million | -10.99% |
| Total Change | $- | 5.71% |
Book Value vs Market Value Analysis
This analysis compares Aprea Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.23x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $-50.82 | $0.82 | x |
| 2018-12-31 | $-73.09 | $0.82 | x |
| 2019-12-31 | $123.64 | $0.82 | x |
| 2020-12-31 | $73.24 | $0.82 | x |
| 2021-12-31 | $46.51 | $0.82 | x |
| 2022-12-31 | $309.51 | $0.82 | x |
| 2023-12-31 | $5.05 | $0.82 | x |
| 2024-12-31 | $3.50 | $0.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aprea Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -67.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -862.43%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.24x
- Recent ROE (-67.12%) is above the historical average (-68.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 0.00% | -5193.06% | 0.22x | 0.00x | $-3.31 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $271.92K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $133.33K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.61 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.38 Million |
| 2019 | -22.58% | 0.00% | 0.00x | 1.08x | $-40.48 Million |
| 2020 | -69.66% | 0.00% | 0.00x | 1.20x | $-61.66 Million |
| 2021 | -73.80% | 0.00% | 0.00x | 1.15x | $-41.49 Million |
| 2022 | -439.34% | 0.00% | 0.00x | 1.18x | $-115.23 Million |
| 2023 | -78.22% | -2449.59% | 0.03x | 1.24x | $-16.11 Million |
| 2024 | -67.12% | -862.43% | 0.06x | 1.24x | $-14.89 Million |
Industry Comparison
This section compares Aprea Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aprea Therapeutics Inc (APRE) | $11.64 Million | 0.00% | 0.23x | $9.37 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tum… Read more